Body Mass Index and Immunotherapy Outcomes
Does body mass index reliably predict treatment outcomes or adverse events for patients receiving cancer immunotherapy?
Following this evidence dossier can show whether reported BMI associations hold across cancer types and immunotherapy settings. That may help readers judge how much weight to give BMI when interpreting treatment outcomes.
Where it stands now
Main bottleneck
Current evidence contains review and meta-analysis titles across broad and cancer-specific settings, but does not establish whether BMI is a consistent, independent predictor across those settings.
Watch next
Watch for a cancer-specific analysis with primary patient data that tests whether BMI associations with immunotherapy outcomes persist after accounting for differences among patients and treatments.
Progress timeline
How the evidence has changed over time.
2025 · 1 update
- How did survival differ by weight during immunotherapy for head and neck cancer?Source date 2025-02-01
Since the previous research note · Earlier expectation not tested
Track continuity
Since the previous research note: How did body mass index relate to survival across kidney cancer treatments?
Previous expectation: Better validated, treatment-specific body-composition measures might help tailor expectations for first-line kidney cancer care.
What this study adds: This synthesis examines BMI and survival in a different cancer population receiving immunotherapy; its underweight association spans both reported survival measures. It does not compare first-line kidney cancer regimens or test whether body composition adds reliable individual predictions.
Current research note
2024 · 1 update
- How did body mass index relate to survival across kidney cancer treatments?Changed directionSource date 2024-09-01
Since the previous research note · Changed direction
Track continuity
Since the previous research note: What can body mass index tell us about immunotherapy outcomes?
Previous expectation: A validated BMI-related measure might help clinicians anticipate checkpoint-treatment benefit and immune side effects across patient groups.
What this study adds: This 2024 synthesis narrowed the question to first-line metastatic kidney cancer and found that the higher-BMI overall-survival association appeared in cohorts receiving checkpoint therapy with a targeted drug, but was not detected in predominantly checkpoint-only cohorts. Its progression finding also points away from a single favorable BMI story.
Current research note
2021 · 1 update
- What can body mass index tell us about immunotherapy outcomes?Source date 2021-01-29
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.